Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-04-09 Annual Report
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年04月法人說明會簡報 — 179520240409M001.pdf
Annual Report Classification · 95% confidence The document is a detailed presentation containing comprehensive financial data for the fiscal year 2023, including consolidated revenue, operating profit, net income, earnings per share, and growth percentages. It also includes operational highlights, product approvals, market expansions, and future outlook for 2024. The presence of detailed financial tables, year-over-year comparisons, and management commentary on business performance and outlook indicates this is a full annual financial report. The document length (7,957 characters) and content depth confirm it is not a brief announcement or a simple presentation but a substantive report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-09 Chinese
113年04月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a scheduled corporate event, specifically a '法人說明會' which translates to 'investor presentation' or 'institutional investor briefing'. It includes the company code, name, date, time, location, and links to presentation materials and video. The content is focused on a scheduled presentation of financial and operational overview by the company at a themed earnings presentation event. The document length is short (1117 characters) and it is not a full report but rather an announcement or summary of an investor presentation event. This matches the definition of an Investor Presentation (IP) filing type, which is a detailed presentation for investors focusing on financials, strategy, and market position. Therefore, the correct classification is Investor Presentation (IP).
2024-04-09 Chinese
113年03月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tabular data showing shareholdings and changes in shareholdings by insiders such as directors, general managers, and vice general managers. It includes information on stock types, numbers held at different times, increases and decreases in holdings, and notes on identities. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full annual or quarterly report, earnings release, or any other report type. The document is not a brief announcement but a detailed insider shareholding report. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2024-04-03 Chinese
113年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders and directors of the company 美時化學製藥股份有限公司. It lists share counts, pledged shares, and related insider information. There is no indication of financial results, earnings, management discussion, or report publication. The content focuses on insider shareholdings and pledges, which corresponds to insider transactions or director dealings. Given the detailed insider shareholding data and the nature of the content, this fits best with the category 'Director's Dealing' (DIRS). The document length is 4480 characters, which is sufficient for a detailed insider shareholding report rather than a brief announcement. Therefore, the classification is DIRS with high confidence.
2024-04-03 Chinese
本公司受邀參加臺灣證券交易所舉辦之113年「生技醫療產業」主題式業績發表會
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company 1795 美時 being invited to participate in a themed earnings presentation event organized by the Taiwan Stock Exchange. It specifies the date, time, and location of the investor presentation and mentions that the company will explain its financial and operational overview. The document is short (699 characters) and serves as a notice of an upcoming investor presentation rather than containing the presentation itself or detailed financial data. Therefore, it fits the category of an Investor Presentation (IP) announcement or invitation. Given the content and length, the best classification is Investor Presentation (IP).
2024-04-03 Chinese
113年03月法人說明會簡報 — 179520240328E001.pdf
Investor Presentation Classification · 95% confidence The document is titled '4Q23 and 2023 EARNINGS RESULTS Investor meeting Presentation' and contains detailed financial results for the full year 2023 and the fourth quarter of 2023, including revenue, gross profit, net income, EPS, margins, and segment performance. It also includes business highlights, product launches, R&D pipeline, and a business outlook for 2024. The content is structured as a presentation with slides and charts, aimed at investors, focusing on financial performance, business strategy, and future outlook. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. The document is not a brief earnings release (ER) since it contains extensive data and analysis, nor is it a full annual report (10-K) or interim report (IR) as it lacks comprehensive statutory financial statements and notes. Therefore, the best classification is Investor Presentation (IP).
2024-03-28 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.